Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NATRIURETIC Trial
NCT04535960Phase 2Completed
- Sponsor
- University Health Network
- Start
- Mar 2019
- Primary completion
- Mar 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Liraglutide -> Combination with Empagliflozin -> Combination (2 arms). Primary endpoint: Proximal tubular natriuresis (fractional excretion of sodium) at 12 weeks. Started Mar 2019; status: completed.
02
Drugs
empagliflozinliraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04535960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04535960.